Icu Medical Inc/de (ICUI): Robert S Swinney , director of Icu Medical Inc/de sold 1,875 shares on Apr 11, 2016. The Insider selling transaction was disclosed on Apr 11, 2016 to the Securities and Exchange Commission. The shares were sold at $101.35 per share for a total value of $190,031.25.
Company has been under the radar of several Street Analysts.ICU Medical Incorporated is Initiated by Gabelli & Co to Buy and the brokerage firm has set the Price Target at $128. The Rating was issued on Mar 11, 2016.
Currently the company Insiders own 17.5% of ICU Medical Incorporated shares according to the proxy statements.In the past twelve weeks, the net percent change held by company insiders has changed by -78.27%.Institutional Investors own 86.82% of ICU Medical Incorporated shares.During last six month period, the net percent change held by insiders has seen a change of -23.06%.
Shares of ICU Medical Incorporated (ICUI) ended Monday, Apr 11, 2016 session in red amid volatile trading. The shares closed down -1.7 points or -1.68% at $99.79 with 85,008 shares getting traded. Post opening the session at $101.35, the shares hit an intraday low of $99.245 and an intraday high of $101.946 and the price vacillated in this range throughout the day. The company has a market cap of $1,609 M and the number of outstanding shares has been calculated to be 1,61,19,568 shares. The 52-week high of ICU Medical Incorporated is $124.69 and the 52-week low is $84.02.
ICU Medical Inc. is engaged in the development manufacturing and sales of medical devices used in infusion therapy oncology and critical care applications. The Companys product line includes needlefree connection devices custom infusion sets closed system transfer devices (CSTD) for the handling of hazardous drugs advanced sensor catheters needlefree closed blood sampling systems disposable pressure transducer systems and innovative hemodynamic monitoring systems. The Companys products are used in acute care hospitals and ambulatory clinics in more than 60 countries worldwide. Its products are categorized into three market segments: Infusion Therapy Critical Care and Oncology. Its primary products include MicroClave and MicroClave Clear Anti-Microbial MicroClave Tego needlefree hemodialysis connector Transpac disposable pressure transducers Pulmonary artery thermodilution catheters ChemoLock CSTD and components and Diana hazardous drug compounding system among others.